Blog

Rodrigo Sánchez-Bayona: RWE study of ovarian cancer patients treated with PARP inhibitors at ESMO Gynaecological Cancers Congress 2024

Photo from Rodrigo Sánchez-Bayona/X

Jul 1, 2024, 13:29

Rodrigo Sánchez-Bayona: RWE study of ovarian cancer patients treated with PARP inhibitors at ESMO Gynaecological Cancers Congress 2024

Rodrigo Sánchez-Bayona, Medical Oncologist specialising in breast and gynecological cancers at 12 de Octubre University Hospital, posted on X:

“Thanks to The European Society for Medical Oncology for the Merit Travel Grant to present our RWE study of ovarian cancer patients treated with PARP inhibitors in Spain, a young oncologist collaborative research, in ESMO Gynaecological Cancers Congress 2024.”

Source: Rodrigo Sánchez-Bayona/X

cancer ESMO Gynaecological Cancers Congress 2024 Merit Travel Grant OncoDaily Oncology Ovarian Cancer PARP inhibitors Rodrigo Sánchez-Bayona RWE study The European Society for Medical Oncology

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers